A new clinical trial involving tirzepatide was posted on August 3, 2026. The study is titled "Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity." It is registered as a Phase 3 trial under identifier NCT07738276. The trial's current status is listed as not yet recruiting, meaning participant enrollment has not begun. According to the registration, the study aims to examine tirzepatide's efficacy and safety related to functional capacity in a patient population with reduced ejection fraction heart failure and obesity. No results, outcomes, or efficacy data have been posted as part of this update. The trial record reflects only the study design and current recruitment status as of the listed date. Further details, including enrollment timelines and study completion, are expected to be updated on the official registry as the trial progresses. Readers interested in tirzepatide's approved uses and background can consult the compound overview for additional context.
Tirzepatide Phase 3 Trial in Heart Failure Patients With Obesity Registered
See the full tirzepatide overview
Source: https://clinicaltrials.gov/study/NCT07738276